top of page
  • Recruiting
    • Dec 9, 2020

NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies

Updated: May 25, 2022

FT538

induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538


FT538


NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies


This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.


Sponsor

Fate Therapeutics

 

ClinicalTrials.gov Identifier: NCT04614636


Official Title: A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma


First Posted : November 4, 2020


Click here for details on ClinicalTrials.gov

 

FT 538

iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 (Code C176623)

FT 538

FT-538

FT538

induced pluri